Intarcia raises $210M to advance once-yearly diabetes drug

11/16/2012 | American City Business Journals · Mass High Tech (Boston)

Intarcia Therapeutics raised $210 million in a preferred stock sale and private debt placement. The company will use the proceeds to initiate late-stage trials of ITCA-650, an experimental type 2 diabetes drug intended to be administered once a year. Intarcia plans to submit the drug for approval in 2015.

View Full Article in:

American City Business Journals · Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA